15/06/2026 SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy XBiotech launched Phase 2 trial evaluating vilamakitug for the treatment of active axial spondyloarthritis Spyre announced Part A results from Phase 2 trial of SPY002 in moderate-to-severe UC SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis (Ref) SynAct Pharma AB